Plans for Canakinumab CV Indication Hit Roadblock With FDA Plans for Canakinumab CV Indication Hit Roadblock With FDA

The anti-inflammatory drug made a big splash in the CANTOS trial, but the agency is calling for more data on responders.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news
More News: Cardiology | Health | Heart